Azacitidine + Azacitidine plus Deferasirox
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
High Risk MDS
Conditions
High Risk MDS
Trial Timeline
Sep 11, 2014 → Jun 26, 2015
NCT ID
NCT02159040About Azacitidine + Azacitidine plus Deferasirox
Azacitidine + Azacitidine plus Deferasirox is a phase 2 stage product being developed by Novartis for High Risk MDS. The current trial status is terminated. This product is registered under clinical trial identifier NCT02159040. Target conditions include High Risk MDS.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02159040 | Phase 2 | Terminated |
Competing Products
20 competing products in High Risk MDS